Dr. Paauw is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
116 Nationwide Drive
Lynchburg, VA 24502Phone+1 434-947-3984Fax+1 434-947-5950
Education & Training
- Texas A&M College of Medicine-Scott and White Medical Center (Temple)Residency, Ophthalmology, 2005 - 2009
- University of Michigan Medical SchoolClass of 2005
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- VA State Medical License 2015 - 2026
- MO State Medical License 2010 - 2016
- FL State Medical License 2009 - 2011
- American Board of Ophthalmology Ophthalmology
Clinical Trials
- Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Start of enrollment: 2023 Apr 20
Roles: Contact
Publications & Presentations
PubMed
- Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials.Elizabeth Yeu, James D Paauw, Patrick Vollmer, Gregg J Berdy, William E Whitson
Ophthalmology and Therapy. 2025-01-28 - Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.Miriam Kolko, Andrew J Tatham, Kin Sheng Lim, Anthony P Wells, Michael Shiu
American Journal of Ophthalmology. 2025-01-10 - 1 citationsLong-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study.Ehsan Sadri, James D Paauw, Joseph B Ciolino, Lisa Nijm, Blake Simmons
Cornea. 2024-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: